Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00347841 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
A Phase 4 study of Glaucoma, sponsored by Innovative Medical.
- Completed
- Registry status
- Phase 4
- Development phase
- 1
- Study location
NCT00347841 is a Phase 4 study of Glaucoma that has completed, run by Innovative Medical. The trial reports 1 study location across 1 state.
The verdict
NCT00347841, a Phase 4 study of Glaucoma, has completed, sponsored by Innovative Medical.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1
- Study location
Study Summary
To evaluate the IOP-lowering efficacy of bimatoprost 0.03% in patients found to be low-responders to latanoprost therapy.
Conditions Studied
Interventions
- DRUG Bimatoprost 0.03%, Latanoprost
Study Locations (1)
Pennsylvania
- Dr. Noecker - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00347841
The ClinicalTrials.gov registry entry for NCT00347841 describes a study currently listed as completed, categorized as Phase 4. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Innovative Medical, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which Bimatoprost 0.03%, Latanoprost is the first listed.
NCT00347841 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00347841 about?
NCT00347841 is a clinical study titled "Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost". To evaluate the IOP-lowering efficacy of bimatoprost 0.03% in patients found to be low-responders to latanoprost therapy.
What is the current status of trial NCT00347841?
This trial is currently completed. It is a Phase 4 study.
What conditions does trial NCT00347841 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT00347841?
The interventions under investigation include: Bimatoprost 0.03%, Latanoprost (DRUG).
Who is sponsoring clinical trial NCT00347841?
This trial is sponsored by Innovative Medical, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00347841 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Retinal Blood Flow and Autoregulation
RECRUITING · Phase 4
-
Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
RECRUITING · Phase 4
-
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
RECRUITING · Phase 4
-
Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
COMPLETED · Phase 4
-
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance
COMPLETED · Phase 4
-
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.